Skip to main content
. 2019 Apr 10;20(7):1767. doi: 10.3390/ijms20071767

Figure 5.

Figure 5

The effects of TRPA1 agonist allyl isothiocyanate (AITC) on the expression of inflammation markers and ECM molecules in IL-1β-treated cells. Gene expression of (A) IL-6 and (D) IL-8 in IVD cells treated with 10 ng/mL IL-1β ± 3 and 10 μM AITC. Protein release of (B) IL-6 and (E) IL-8 in IVD cells that were treated with 10 ng/mL IL-1β ± 3 and 10 μM AITC. Gene expression of (C) NGF, (F) COX-2, (G) ADAMTS4, (H) ADAMTS5, (J) MMP1, (K) MMP3, (I) TIMP1 and (L) TIMP2, (M) COL1A1, (N) COL2A1, and (O) Aggrecan in IVD cells that were treated with 10 ng/mL IL-1β ± 3 or 10 μM AITC. Graphs show gene expression and protein release calculated relative to IL-1β treatment (mean ± SD, n = 3–4). Asterisks indicate statistical significance (* p < 0.05, Kruskal–Wallis test and Dunn’s multiple comparison test).